0.86
-0.0035(-0.41%)
Currency In USD
| Previous Close | 0.86 |
| Open | 0.86 |
| Day High | 0.89 |
| Day Low | 0.85 |
| 52-Week High | 1.66 |
| 52-Week Low | 0.55 |
| Volume | 406,522 |
| Average Volume | 848,151 |
| Market Cap | 111.06M |
| PE | -3.91 |
| EPS | -0.22 |
| Moving Average 50 Days | 0.89 |
| Moving Average 200 Days | 0.83 |
| Change | -0 |
If you invested $1000 in Atossa Therapeutics, Inc. (ATOS) 10 years ago, it would be worth $7.13 as of November 04, 2025 at a share price of $0.86. Whereas If you bought $1000 worth of Atossa Therapeutics, Inc. (ATOS) shares 5 years ago, it would be worth $558.31 as of November 04, 2025 at a share price of $0.86.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Atossa Therapeutics Appoints CORE IR for Investor Relations, Shareholder Communications and Public Relations Services
GlobeNewswire Inc.
Sep 17, 2025 12:00 PM GMT
Engagement to enhance investor awareness, strengthen shareholder engagement, and broaden reach to target institutional and retail audiencesSEATTLE, Sept. 17, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS; “Atossa” or the “Company
Atossa Therapeutics Announces Issuance of U.S. Patent No. 12,281,056, Including 58 Claims Covering Various Formulations for its (Z)-endoxifen Portfolio
GlobeNewswire Inc.
Apr 30, 2025 12:45 PM GMT
SEATTLE, April 30, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today announced that the United States
Atossa Therapeutics Proposes Potentially Groundbreaking Study Aimed at Reducing Interval Breast Cancer in High-Risk Women at AACR 2025
GlobeNewswire Inc.
Apr 29, 2025 12:45 PM GMT
SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”), a clinical-stage biopharmaceutical company developing innovative medicines for breast cancer, today outlined a framework for a pioneer